Correlation Between Autolus Therapeutics and Bolt Biotherapeutics
Can any of the company-specific risk be diversified away by investing in both Autolus Therapeutics and Bolt Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Autolus Therapeutics and Bolt Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Autolus Therapeutics and Bolt Biotherapeutics, you can compare the effects of market volatilities on Autolus Therapeutics and Bolt Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Autolus Therapeutics with a short position of Bolt Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Autolus Therapeutics and Bolt Biotherapeutics.
Diversification Opportunities for Autolus Therapeutics and Bolt Biotherapeutics
0.58 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Autolus and Bolt is 0.58. Overlapping area represents the amount of risk that can be diversified away by holding Autolus Therapeutics and Bolt Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bolt Biotherapeutics and Autolus Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Autolus Therapeutics are associated (or correlated) with Bolt Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bolt Biotherapeutics has no effect on the direction of Autolus Therapeutics i.e., Autolus Therapeutics and Bolt Biotherapeutics go up and down completely randomly.
Pair Corralation between Autolus Therapeutics and Bolt Biotherapeutics
Given the investment horizon of 90 days Autolus Therapeutics is expected to generate 1.18 times more return on investment than Bolt Biotherapeutics. However, Autolus Therapeutics is 1.18 times more volatile than Bolt Biotherapeutics. It trades about 0.05 of its potential returns per unit of risk. Bolt Biotherapeutics is currently generating about -0.02 per unit of risk. If you would invest 180.00 in Autolus Therapeutics on August 31, 2024 and sell it today you would earn a total of 152.00 from holding Autolus Therapeutics or generate 84.44% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Autolus Therapeutics vs. Bolt Biotherapeutics
Performance |
Timeline |
Autolus Therapeutics |
Bolt Biotherapeutics |
Autolus Therapeutics and Bolt Biotherapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Autolus Therapeutics and Bolt Biotherapeutics
The main advantage of trading using opposite Autolus Therapeutics and Bolt Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Autolus Therapeutics position performs unexpectedly, Bolt Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bolt Biotherapeutics will offset losses from the drop in Bolt Biotherapeutics' long position.Autolus Therapeutics vs. Cullinan Oncology LLC | Autolus Therapeutics vs. Bolt Biotherapeutics | Autolus Therapeutics vs. Day One Biopharmaceuticals | Autolus Therapeutics vs. Lyra Therapeutics |
Bolt Biotherapeutics vs. Cue Biopharma | Bolt Biotherapeutics vs. Eliem Therapeutics | Bolt Biotherapeutics vs. Inhibrx | Bolt Biotherapeutics vs. Molecular Partners AG |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Complementary Tools
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |